Analysts Anticipate OrthoPediatrics Corp. (NASDAQ:KIDS) Will Post Quarterly Sales of $26.85 Million

Brokerages predict that OrthoPediatrics Corp. (NASDAQ:KIDS) will report sales of $26.85 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for OrthoPediatrics’ earnings, with the lowest sales estimate coming in at $26.20 million and the highest estimate coming in at $27.34 million. OrthoPediatrics reported sales of $22.21 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 20.9%. The business is scheduled to issue its next earnings report on Wednesday, November 3rd.

According to Zacks, analysts expect that OrthoPediatrics will report full year sales of $99.22 million for the current fiscal year, with estimates ranging from $99.00 million to $99.57 million. For the next fiscal year, analysts anticipate that the firm will report sales of $120.99 million, with estimates ranging from $117.89 million to $126.20 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow OrthoPediatrics.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Wednesday, August 4th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.10. OrthoPediatrics had a negative net margin of 36.61% and a negative return on equity of 7.64%. The company had revenue of $26.70 million for the quarter, compared to analysts’ expectations of $24.14 million.

Several analysts recently weighed in on KIDS shares. JMP Securities boosted their price objective on shares of OrthoPediatrics from $70.00 to $77.00 and gave the stock an “outperform” rating in a research note on Friday, August 6th. Zacks Investment Research raised shares of OrthoPediatrics from a “hold” rating to a “buy” rating and set a $77.00 price objective on the stock in a research note on Wednesday, August 11th. Needham & Company LLC upped their price target on shares of OrthoPediatrics from $70.00 to $77.00 and gave the company a “buy” rating in a research report on Monday, June 14th. Finally, Piper Sandler upped their price target on shares of OrthoPediatrics from $70.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, August 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, OrthoPediatrics has an average rating of “Buy” and a consensus price target of $73.14.

Shares of OrthoPediatrics stock traded up $1.03 during trading on Tuesday, hitting $69.65. The company’s stock had a trading volume of 51,307 shares, compared to its average volume of 141,266. OrthoPediatrics has a 52 week low of $38.01 and a 52 week high of $72.50. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -40.97 and a beta of 0.69. The stock has a 50-day moving average price of $64.46 and a two-hundred day moving average price of $58.46.

In other news, CFO Fred Hite sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 2nd. The shares were sold at an average price of $71.50, for a total transaction of $357,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Jennifer N. Pritzker acquired 400 shares of the company’s stock in a transaction dated Friday, August 27th. The shares were bought at an average price of $64.55 per share, for a total transaction of $25,820.00. The disclosure for this purchase can be found here. Insiders have sold 11,321 shares of company stock worth $780,217 in the last quarter. Company insiders own 30.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of KIDS. Parametric Portfolio Associates LLC purchased a new stake in OrthoPediatrics in the 2nd quarter valued at about $274,000. Morgan Stanley increased its stake in OrthoPediatrics by 708.1% in the 2nd quarter. Morgan Stanley now owns 81,646 shares of the company’s stock valued at $5,159,000 after buying an additional 71,543 shares during the last quarter. Invesco Ltd. increased its stake in OrthoPediatrics by 0.7% in the 2nd quarter. Invesco Ltd. now owns 411,762 shares of the company’s stock valued at $26,015,000 after buying an additional 2,920 shares during the last quarter. Lisanti Capital Growth LLC purchased a new stake in OrthoPediatrics in the 2nd quarter valued at about $5,826,000. Finally, Metropolitan Life Insurance Co NY increased its stake in OrthoPediatrics by 110,350.0% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 4,418 shares of the company’s stock valued at $279,000 after buying an additional 4,414 shares during the last quarter. Institutional investors own 76.18% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard.

See Also: What are momentum indicators and what do they show?

Get a free copy of the Zacks research report on OrthoPediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.